VYGR News & Analysis

Voyager Therapeutics (VYGR) Stock Rating Reiterated on Pipeline Progress

H.C. Wainwright has reiterated its stock rating for Voyager Therapeutics (VYGR) due to positive developments in its pipeline. The firm's analysts are focusing on the progress made with ongoing clinical trials and research initiatives. These developments could have significant implications for VYGR's stock performance, as successful results may bolster investor confidence and market interest. The continuation of these pipeline efforts is crucial for VYGR's future growth and credibility in the biotech sector.